Successful treatment with entecavir for reactivation of hepatitis B virus following systemic chemotherapy in a hepatitis B surface antigen-negative patient with colorectal cancer

Internal Medicine

Volumn 53, Issue 16, 2014, Pages 1759-1762

  Okagawa, Yutaka ^a,b   Takada, Kohichi ^b   Hisai, Hiroyuki ^a   Koshiba, Yutaka ^a   Wada, Hironori ^a   Miyazaki, Etsu ^a   Kanari, Yusuke ^b   Kawano, Yutaka ^b   Iyama, Satoshi ^b   Hayashi, Tsuyoshi ^b   Sato, Tsutomu ^b   Sato, Yasushi ^b   Miyanishi, Koji ^b   Kobune, Masayoshi ^b   Takimoto, Rishu ^b   Kato, Junji ^b  

^a Date Red Cross Hospital   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Entecavir; FOLFOX; HBV reactivation

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; ENTECAVIR; FOLFOX; GLYCYRRHIZIC ACID; HEPATITIS B SURFACE ANTIGEN; PROTHROMBIN; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT; FLUOROURACIL; FOLINIC ACID; GUANINE; PLATINUM COMPLEX;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CHEMILUMINESCENCE IMMUNOASSAY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FATIGUE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CYST; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PALLIATIVE THERAPY; PELVIS EXENTERATION; RADIOFREQUENCY ABLATION; SEVERE HEPATIC IMPAIRMENT; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; COMPLICATION; DRUG EFFECTS; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; COLORECTAL NEOPLASMS; FLUOROURACIL; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; LEUCOVORIN; MALE; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84906767599     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.1970     Document Type: Article

References (17)

1. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49: 652-657, 2008.
2. Paraskevis D, Beloukas A, Haida C, et al. Development of a new ultra sensitive real-time-PCR assay (ultra sensitive RTQ-PCR) for the quantification of HBV-DNA. Virol J 7: 57, 2010.
3. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131: 59-68, 2006.
4. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis virus reactivation during anticancer therapy. Hepatology 43: 209-220, 2006.
5. Hagiwara S, Sakurai T, Nishina S, et al. Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers. Dig Dis 30: 541-546, 2012.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
7. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28: 264-271, 2010.
8. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351, 2004.
9. Kuebler JP, Wieand HS, O’Connell MJ, Wolmark N. Oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: re-sults from NSABP Protocol C-07. J Clin Oncol 25: 2198-2204, 2007.
10. Ling WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumors. Br J Cancer 108: 1931-1935, 2013.
11. LCY Lui, RTT Chan, CCH, Kwok, A et al. Reactivation of Hepatitis B after Irinotecan. HK J Radiol 7: 72-75, 2004.
12. Tsubouchi H, Kumada H, Kiyosawa K, et al. Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis. Kanzo (Acta Hepatol Jpn) 50: 38-42, 2009 (in Japanese, Abstract in English).
13. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trail of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patient with lymphoma and resolved hepatitis B. J Clin Oncol 31: 2765-2772, 2013.
14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 50: 661-662, 2009.
15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 50: 227-242, 2009.
16. Tanaka Y, Sugauchi F, Matuura K, et al. Evaluation of hepatitis B virus genotyping EIA kit. Rinsho Byori (The Official Journal of Japanese Society of Laboratory Medicine) 57: 42-47, 2009 (in Japanese, Abstract in English).
17. Suh DJ, Um SH, Herrmann E, et al. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother 54: 1242-1247, 2010.